Unstructured treatment interruption of antiretroviral therapy in clinical practice: A systematic review

Tropical Medicine and International Health

Volumn 16, Issue 10, 2011, Pages 1297-1313

  Kranzer, Katharina ^a   Ford, Nathan ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Antiretroviral therapy; HIV; Unstructured treatment interruption

Indexed keywords

ANTIRETROVIRUS AGENT; METHADONE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DEVELOPING WORLD; DISEASE TREATMENT; DRUG; ETHNIC MINORITY; HEALTH IMPACT; HEALTH RISK; HEALTH SERVICES; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE SYSTEM; MEDICINE; MENTAL HEALTH; MORTALITY RISK; RISK FACTOR; SOCIOECONOMIC CONDITIONS; TOXICITY;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; DRUG COST; DRUG WITHDRAWAL; ETHNIC GROUP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENTAL HEALTH SERVICE; OPPORTUNISTIC INFECTION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT COUNSELING; PHARMACY; REVIEW; RISK FACTOR; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VOMITING;

AGE FACTORS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; MALE; PRESCRIPTION DRUGS; REMINDER SYSTEMS; RISK FACTORS; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

AFRICA;

EID: 80052873078     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2011.02828.x     Document Type: Review

References (109)

1. Achenbach CJ, Till M, Palella FJ et al. (2005) Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA. HIV Medicine 6, 7-12.
2. Adeyemi A & Olaogun O (2006) Challenges to management of HIV patients in rural and urban communities in South-western Nigeria. XVI International AIDS Conference. Toronto, Canada.
3. Ahonkhai A, Noubary F, Munro A et al. (2011) Not all are lost: early death, care interruption, loss to follow-up in a large South African community treatment program. 18th Conference on Retroviruses and Opportunistic Infections. Boston, USA.
4. Ammassari A, Trotta MP, Marconi P et al. (2004) Incorporating patients' suggestions in individualized intervention program for improving adherence to antiretrovirals. XV International AIDS Conference. Bangkok, Thailand.
5. Ayuo P, Braitstein P, Nyandiko W et al. (2008) Frequency and factors associated with loss to follow-up (LTFU) and treatment interruptions (TI) among pregnant women initiating combination antiretroviral therapy (cART) in Western Kenya. XVII International AIDS Conference. Mexico City, Mexico.
6. Bae JW, Guyer W, Grimm K & Altice FL (2011) Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS 25, 279-290.
7. Bangsberg DR, Acosta EP, Gupta R et al. (2006) Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 20, 223-231.
8. Bansi LK, Benzie AA, Phillips AN et al. (2008) Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? AIDS 22, 349-356.
9. Bastard M, Koita Fall MB, Laniece I et al. (2011) Revisiting long-term adherence to HAART in Senegal using latent class analysis. Journal of Acquired Immune Deficiency Syndromes 57, 55-61.
10. Bedimo R, Chen RY, Westfall AO et al. (2006) Sustained HIV viral suppression following treatment interruption: an observational study. AIDS Research & Human Retroviruses 22, 40-44.
11. Berenguer J, Perez-Elias MJ, Bellon JM et al. (2004) Abacavir, lamivudine and zidovudine (ABC/3TC/ZDV) in antiretroviral-naive HIV-infected patients: multicenter observational cohort from Spain. XV International AIDS Conference. Bangkok, Thailand.
12. Boileau C, Nguyen VK, Sylla M et al. (2008) Low prevalence of detectable HIV plasma viremia in patients treated with antiretroviral therapy in Burkina Faso and Mali. Journal of Acquired Immune Deficiency Syndromes: JAIDS 48, 476-484.
13. Boyd MA (2009) Improvements in antiretroviral therapy outcomes over calendar time. Current Opinion in HIV and AIDS 4, 194-199.
14. Braitstein P, Mwangi A, Wools-Kaloustian K et al. (2007) Frequency, causes, and factors associated with treatment interruptions (TI) among adults initiating highly active antiretroviral therapy (HAART) in Western Kenya. 4th Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia.
15. Brinkhof MW, Pujades-Rodriguez M & Egger M (2009) Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS ONE 4, e5790.
16. Burton CT, Nelson MR, Hay P et al. (2005) Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection. Clinical & Experimental Immunology 142, 354-361.
17. Byakika-Tusiime J, Crane J, Oyugi JH et al. (2009) Longitudinal antiretroviral adherence in HIV+ Ugandan parents and their children initiating HAART in the MTCT-Plus family treatment model: role of depression in declining adherence over time. AIDS and Behavior 13 (Suppl. 1), 82-91.
18. Calmy A, Hirschel B, Cooper DA & Carr A (2007) Clinical update: adverse effects of antiretroviral therapy. Lancet 370, 12-14.
19. Chen RY, Westfall AO, Raper JL et al. (2002) Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice. AIDS Research & Human Retroviruses 18, 909-916.
20. Compostella S, Zeni C, Antonelli S et al. (2005) The psychological reasons and consequences of unstructured therapy interruptions in HIV+ subjects. The 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil.
21. Cramer JA (2004) A systematic review of adherence with medications for diabetes. Diabetes Care 27, 1218-1224.
22. Cramer JA, Roy A, Burrell A et al. (2008) Medication compliance and persistence: terminology and definitions. Value in Health 11, 44-47.
23. Das-Douglas M, Riley ED, Ragland K et al. (2009) Implementation of the medicare part D prescription drug benefit is associated with antiretroviral therapy interruptions. AIDS and Behavior 13, 1-9.
24. Datay MI, Boulle A, Mant D & Yudkin P (2010) Associations with virologic treatment failure in adults on antiretroviral therapy in South Africa. Journal of Acquired Immune Deficiency Syndromes 54, 489-495.
25. Egger M, May M, Chene G et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360, 119-129.
26. Ekstrand ML, Chandy S, Steward WT et al. (2008) Barriers to long-term maintenance of HAART adherence and viral suppression in India. XVII International AIDS Conference. Mexico City, Mexico.
27. Ekstrand ML, Shet A, Chandy S et al. (2010) Suboptimal adherence associated with virologic failure and resistance mutations among patients on 1st line HAART in Bandalore, India. XVIII International AIDS Conference. Vienna, Austria.
28. El-Sadr WM, Lundgren JD, Neaton JD et al. (2006) CD4+ count-guided interruption of antiretroviral treatment. New England Journal of Medicine 355, 2283-2296.
29. Floyd S, Molesworth A, Dube A et al. (2010) Population-level reduction in adult mortality after extension of free anti-retroviral therapy provision into rural areas in northern Malawi. PLoS ONE 5, e13499.
30. Gandhi M, Ameli N, Liegler T et al. (2004) Prevalence and predictors of treatment interruptions in a longitudinal cohort study in women. XV International AIDS Conference. Bangkok, Thailand.
31. Garcia De Olalla P, Knobel H, Carmona A et al. (2002) Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 30, 105-110.
32. Giard M, Boibieux A, Ponceau B et al. (2005) [Treatment interruption in HIV infected patients: clinical and biological evolution]. Médecine et Maladies Infectieuses 35, 525-529.
33. Gibb DM, Duong T, Leclezio VA et al. (2004) Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection. Pediatric Infectious Disease Journal 23, 446-450.
34. Glass TR, De Geest S, Weber R et al. (2006) Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes: JAIDS 41, 385-392.
35. Glass TR, Battegay M, Cavassini M et al. (2010) Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes 54, 197-203.
36. Gonzalez A, Knobel H, Guelar A et al. (2003) Risks and benefits after treatment interruption of antiretroviral therapy in the clinical practice setting. The 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France.
37. Grierson JG, Misson SA & Pitts MK (2004) Correlates of antiretroviral treatment breaks. HIV Medicine 5, 34-39.
38. Grierson J, Thorpe R & Pitts MK (2005) Motivation and consequences of treatment interruptions from the patient perspective. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janerio, Brazil.
39. Hogg RS, Heath K, Bangsberg D et al. (2002) Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1year of follow-up. AIDS 16, 1051-1058.
40. Holkmann Olsen C, Mocroft A, Kirk O et al. (2007) Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Medicine 8, 96-104.
41. Hull M, Joy R, Hogg R & Montaner J (2006) Modelling CD4 cell count decline during treatment interruption stratified by pre-treatment CD4 nadir. XVI International AIDS Conference. Toronto, Canada.
42. Jackevicius CA, Mamdani M & Tu JV (2002) Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288, 462-467.
43. Jahn A, Floyd S, Crampin AC et al. (2008) Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 371, 1603-1611.
44. Kaptue L, Kemkuining J, Kenmogne P & Kaptue B (2002) Follow up of AIDS patients on antiretroviral therapy in Yaounde-Cameroon. XIV International AIDS Conference. Barcelona, Spain.
45. Kaufmann GR, Elzi L, Weber R et al. (2011) Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. AIDS 25, 441-451.
46. Kavasery R, Galai N, Astemborski J et al. (2009) Nonstructured treatment interruptions among injection drug users in Baltimore, MD. Journal of Acquired Immune Deficiency Syndromes: JAIDS 50, 360-366.
47. Knobel H, Alonso J, Casado JL et al. (2002) Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA study. AIDS 16, 605-613.
48. Knobel H, Urbina O, Gonzalez A et al. (2009) Impact of different patterns of nonadherence on the outcome of highly active antiretroviral therapy in patients with long-term follow-up. HIV Medicine 10, 364-369.
49. Kopjar B, Sales AE, Pineros SL et al. (2003) Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. American Journal of Cardiology 92, 1106-1108.
50. Kouanfack C, Montavon C, Laurent C et al. (2008) Evaluation of virological outcome and ARV drug resistance in the national ART program in Cameroon. XVII International AIDS Conference. Mexico City, Mexico.
51. Kranzer K, Lewis JJ, Ford N et al. (2010) Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. Journal of Acquired Immune Deficiency Syndromes 55, e17-e23.
52. Krentz HB, Gill MJ, Krentz HB & Gill MJ (2003) The impact on health-related quality of life of treatment interruptions in HIV-1-infected patients. AIDS 17, 631-633.
53. Laher F, Moodley N, Maphutha M, Mcintyre J & Mohapi L (2007) Virologic suppression after hyperlactataemia-related treatment interruption in an African setting. 4th IAS Conference on HIV Pathogenesis, Treament and Prevention. Sydney, Australia.
54. Landman R, Matheron S, Bouvet E et al. (2003) Effects of antiretroviral treatment interruption in chronic stable patients with virological success. The 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France.
55. Lazar F, Luca AE, Constantin C et al. (2010) Factors influencing treatment adherence of young people. XVIII International AIDS Conference. Vienna, Austria.
56. Lazo M, Gange SJ, Wilson TE et al. (2007) Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clinical Infectious Diseases 45, 1377-1385.
57. Li X, Margolick JB, Conover CS et al. (2005) Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. Journal of Acquired Immune Deficiency Syndromes 38, 320-328.
58. Lima VD, Harrigan R, Bangsberg DR et al. (2009) The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. Journal of Acquired Immune Deficiency Syndromes 50, 529-536.
59. Maggiolo F, Airoldi M, Kleinloog HD et al. (2007) Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clinical Trials 8, 282-292.
60. Mahy M, Stover J, Stanecki K, Stoneburner R & Tassie JM (2010) Estimating the impact of antiretroviral therapy: regional and global estimates of life-years gained among adults. Sexually Transmitted Infections 86 (Suppl. 2), ii67-ii71.
61. Marcellin F, Boyer S, Protopopescu C et al. (2008) Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaounde, Cameroon (EVAL survey, ANRS 12-116). Tropical Medicine & International Health 13, 1470-1478.
62. Martsinovskaya V, Kobyshcha I, Kruglov Y & Weller G (2010) Increasing mortality despite ART scale-up: structure and causes of death in patients with HIV infection in Ukraine. XVIII International AIDS Conference. Vienna, Austria.
63. Mbanya DN (2003) Experiences monitoring AIDS patients on antiretroviral therapy in a resource-limited setting. The 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France.
64. Mills EJ, Nachega JB, Bangsberg DR et al. (2006) Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Medicine 3, e438.
65. Mocroft A, Youle M, Moore A et al. (2001) Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 15, 185-194.
66. Mocroft A, Phillips AN, Soriano V et al. (2005) Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Research & Human Retroviruses 21, 743-752.
67. Moore DM, Zhang W, Yip B et al. (2009) Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme. HIV Medicine 11, 299-307.
68. Mugyenyi P, Walker A, Hakim J et al. (2008) Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts <200cells/microl. AIDS 22, 237-247.
69. Munoz-Moreno JA, Fumaz CR, Prats A et al. (2010) Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning? Journal of Neurovirology 16, 208-218.
70. Murri R, Drapeau CMJ, De Luca A, Fantoni M & Cauda R (2002) Non-structured treatment interruptions are associated with detectable HIV RNA in people taking NNRTI. XIV International AIDS Conference. Barcelona, Spain.
71. Murri R, Guaraldi G, Lupoli P et al. (2009) Rate and predictors of self-chosen drug discontinuations in highly active antiretroviral therapy-treated HIV-positive individuals. AIDS Patient Care and STDs 23, 35-39.
72. Mussini C, Pinti M, Bugarini R et al. (2005) Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study. AIDS 19, 1627-1633.
73. Mussini C, Touloumi G, Bakoyannis G et al. (2009) Magnitude and determinants of CD4 recovery after HAART resumption after 1 cycle of treatment interruption. Journal of Acquired Immune Deficiency Syndromes: JAIDS 52, 588-594.
74. Nachega JB, Mills EJ & Schechter M (2010) Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Current Opinion in HIV and AIDS 5, 70-77.
75. Nacher M, El Guedj M, Vaz T et al. (2006) Risk factors for follow-up interruption of HIV patients in French Guiana. American Journal of Tropical Medicine and Hygiene 74, 915-917.
76. Nieuwkerk PT & Oort FJ (2005) Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. Journal of Acquired Immune Deficiency Syndromes 38, 445-448.
77. Osterberg L & Blaschke T (2005) Adherence to medication. New England Journal of Medicine 353, 487-497.
78. Oyugi JH, Byakika-Tusiime J, Ragland K et al. (2007) Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 21, 965-971.
79. Pai NP, Estes M, Moodie EE, Reingold AL & Tulsky JP (2009) The impact of antiretroviral therapy in a cohort of HIV infected patients going in and out of the San Francisco county jail. PLoS ONE 4, e7115.
80. Palella FJ Jr, Delaney KM, Moorman AC et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine 338, 853-860.
81. Parienti JJ, Massari V, Descamps D et al. (2004) Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clinical Infectious Diseases 38, 1311-1316.
82. Parienti JJ, Das-Douglas M, Massari V et al. (2008) Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS ONE 3, e2783.
83. Parienti JJ, Ragland K, Lucht F et al. (2010) Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication. Clinical Infectious Diseases 50, 1192-1197.
84. Pasquet A, Messou E, Gabillard D et al. (2010) Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Cote d'Ivoire. PLoS ONE 5, e13414.
85. Pavie J, Porcher R, Fournier S et al. (2005) [Treatment interruption in 30 HIV-infected patients with successful viral suppression under highly active antiretroviral treatment]. Presse Medicale 34, 1S8-1S13.
86. Pop-Eleches C, Thirumurthy H, Habyarimana JP et al. (2011) Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS 25, 825-834.
87. Poulton MB, Sabin CA & Fisher M (2003) Immunological changes during treatment interruptions: risk factors and clinical sequelae. AIDS 17, 126-128.
88. Protopopescu C, Roux P, Carrieri MP et al. (2010) Prolonged medically recorded treatment interruptions among HIV-infected patients on highly active antiretroviral therapy with controlled viremia: when physicians have to juggle patient negotiation and guidelines. Journal of Acquired Immune Deficiency Syndromes 53, 544-546.
89. Rosen S, Fox MP & Gill CJ (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Medicine 4, e298.
90. Saitoh A, Foca M, Viani RM et al. (2008) Clinical outcomes after an unstructured treatment interruption in children and adolescents with perinatally acquired HIV infection. Pediatrics 121, e513-e521.
91. Sanchez R, Portilla J, Gimeno A et al. (2007) Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment. Journal of Infection 54, 159-166.
92. Sarmati L, Parisi SG, Andreoni C et al. (2010) Switching of inferred tropism caused by HIV during interruption of antiretroviral therapy. Journal of Clinical Microbiology 48, 2586-2588.
93. Schrooten W, Pelgrom J, Vandenbruaene M et al. (2004) Five-year immunologic outcome of highly active antiretroviral treatment in a clinical setting: results from a single HIV treatment centre. XV International AIDS Conference. Bangkok, Thailand.
94. Seminari E, De Silvestri A, Boschi A & Tinelli C (2008) CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis. AIDS Reviews 10, 236-244.
95. Skiest DJ, Morrow P, Allen B et al. (2004) It is safe to stop antiretroviral therapy in patients with preantiretroviral CD4 cell counts >250cells/microL. Journal of Acquired Immune Deficiency Syndromes 37, 1351-1357.
96. Sommet A, Delpierre C, Cuzin L et al. (2003) [Anti-retroviral treatment interruptions in HIV-infected adults: causes, clinical, immunological and virological consequences]. Revue de Medecine Interne 24, 350-357.
97. Spacek LA, Shihab HM, Kamya MR et al. (2006) Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clinical Infectious Diseases 42, 252-259.
98. Sungkanuparph S, Kiertiburanakul S, Apisarnthanarak A et al. (2007) Rapid CD4 decline after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in a resource-limited setting. AIDS Research and Therapy 4, 26.
99. Taffe P, Rickenbach M, Hirschel B et al. (2002) Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. AIDS 16, 747-755.
100. Tarwater PM, Parish M, Gallant JE et al. (2003) Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. Clinical Infectious Diseases 37, 1541-1548.
101. Touloumi G, Pantazis N, Antoniou A et al. (2006) Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. Journal of Acquired Immune Deficiency Syndromes 42, 554-561.
102. Touloumi G, Pantazis N, Stirnadel HA et al. (2008) Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice. Journal of Acquired Immune Deficiency Syndromes 49, 492-498.
103. Tuldra A, Fumaz CR, Ferrer MJ et al. (2001) Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads. AIDS 15, 1904-1906.
104. Uhagaze B, Ndour T, Sow PS & Rahlenbeck S (2006) Why are drugs not taken? A study into ARV-therapy interruption in Dakar, Senegal. XVI International AIDS Conference. Toronto, Canada.
105. Van Valkengoed IG, Podgany K, Gras L et al. (2003) Therapy interruptions in patients with CD4+ T-cell counts >500 while on HAART. The 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France.
106. Wenkel J, Van Boogard Den W, O'brian D et al. (2006) Adverse consequences of user fees for patients started on antiretroviral therapy (ART) in the governmental HIV-programs in Nigeria. XVI International AIDS conference. Toronto, Canada.
107. Wolf E, Hoffmann C, Procaccianti M et al. (2005) Long-term consequences of treatment interruptions in chronically HIV-1-infected patients. European Journal of Medical Research 10, 56-62.
108. Yozviak JL, Doerfler RE & Woodward WC (2002) Resuppression of virus load after interruption in treatment with nevirapine and 2 nucleoside reverse-transcriptase inhibitors. Clinical Infectious Diseases 34, 547-550.
109. Zhang S, Van Sighem A, Gras L et al. (2010) Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment. Antiviral Therapy 15, 555-562.